These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 34007129)
21. Mesenchymal stem cell-based therapy and exosomes in COVID-19: current trends and prospects. Abdelgawad M; Bakry NS; Farghali AA; Abdel-Latif A; Lotfy A Stem Cell Res Ther; 2021 Aug; 12(1):469. PubMed ID: 34419143 [TBL] [Abstract][Full Text] [Related]
22. Perspectives on mesenchymal stem/progenitor cells and their derivates as potential therapies for lung damage caused by COVID-19. Klimczak A World J Stem Cells; 2020 Sep; 12(9):1013-1022. PubMed ID: 33033561 [TBL] [Abstract][Full Text] [Related]
23. Challenges of mesenchymal stem cells in the clinical treatment of COVID-19. Li L; Zhang X; Wu Y; Xing C; Du H Cell Tissue Res; 2024 Jun; 396(3):293-312. PubMed ID: 38512548 [TBL] [Abstract][Full Text] [Related]
24. Clinical progress in MSC-based therapies for the management of severe COVID-19. Rossello-Gelabert M; Gonzalez-Pujana A; Igartua M; Santos-Vizcaino E; Hernandez RM Cytokine Growth Factor Rev; 2022 Dec; 68():25-36. PubMed ID: 35843774 [TBL] [Abstract][Full Text] [Related]
25. Mesenchymal Stem Cells in the Treatment of COVID-19. Guo BC; Wu KH; Chen CY; Lin WY; Chang YJ; Lee TA; Lin MJ; Wu HP Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834246 [TBL] [Abstract][Full Text] [Related]
26. Mesenchymal stem/stromal cell-based therapies for COVID-19: First iteration of a living systematic review and meta-analysis: MSCs and COVID-19. Kirkham AM; Monaghan M; Bailey AJM; Shorr R; Lalu MM; Fergusson DA; Allan DS Cytotherapy; 2022 Jun; 24(6):639-649. PubMed ID: 35219584 [TBL] [Abstract][Full Text] [Related]
27. COVID-19 and its Therapeutics: Special Emphasis on Mesenchymal Stem Cells Based Therapy. Verma YK; Verma R; Tyagi N; Behl A; Kumar S; Gangenahalli GU Stem Cell Rev Rep; 2021 Feb; 17(1):113-131. PubMed ID: 32920752 [TBL] [Abstract][Full Text] [Related]
28. Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm. Song N; Wakimoto H; Rossignoli F; Bhere D; Ciccocioppo R; Chen KS; Khalsa JK; Mastrolia I; Samarelli AV; Dominici M; Shah K Stem Cells; 2021 Jun; 39(6):707-722. PubMed ID: 33586320 [TBL] [Abstract][Full Text] [Related]
29. Mesenchymal stem cell therapy for severe COVID-19. Shi L; Wang L; Xu R; Zhang C; Xie Y; Liu K; Li T; Hu W; Zhen C; Wang FS Signal Transduct Target Ther; 2021 Sep; 6(1):339. PubMed ID: 34497264 [TBL] [Abstract][Full Text] [Related]
30. Mesenchymal stem cells and their derived exosomes to combat Covid-19. Yousefi Dehbidi M; Goodarzi N; Azhdari MH; Doroudian M Rev Med Virol; 2022 Mar; 32(2):e2281. PubMed ID: 34363275 [TBL] [Abstract][Full Text] [Related]
31. Combination of mesenchymal stem cells and nicorandil: an emerging therapeutic challenge against COVID-19 infection-induced multiple organ dysfunction. Safari A; Lionetti V; Razeghian-Jahromi I Stem Cell Res Ther; 2021 Jul; 12(1):404. PubMed ID: 34266486 [TBL] [Abstract][Full Text] [Related]
32. Current Status of Cell-Based Therapies for COVID-19: Evidence From Mesenchymal Stromal Cells in Sepsis and ARDS. Xu Z; Huang Y; Zhou J; Deng X; He W; Liu X; Li Y; Zhong N; Sang L Front Immunol; 2021; 12():738697. PubMed ID: 34659231 [TBL] [Abstract][Full Text] [Related]
33. Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome? Hamdan H; Hashmi SK; Lazarus H; Gale RP; Qu W; El Fakih R Blood Rev; 2021 Mar; 46():100742. PubMed ID: 32854985 [TBL] [Abstract][Full Text] [Related]